Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

Ohio State researchers find that addition of bevacizumab to the treatment of newly diagnosed brain tumors does not extend patients’ lives

  • Posted: February 20, 2014

Results from a randomized, phase 3 clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) have shown that adding bevacizumab, a drug that inhibits the growth of blood vessels, to the treatment of glioblastoma does not improve patient survival.

Click here to read the full press release.

Click here to read M.D. Anderson release. 


NCI Comprehensive Cancer Center logoAmong the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.